Get the Stockscreener App
5.71
1.24%
0.07
After Hours:
5.81
0.10
+1.75%
Nuvation Bio Inc stock is traded at $5.71, with a volume of 5.37M.
It is up +1.24% in the last 24 hours and down -28.98% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
See More
Previous Close:
$5.64
Open:
$5.67
24h Volume:
5.37M
Relative Volume:
0.74
Market Cap:
$1.96B
Revenue:
-
Net Income/Loss:
$-75.80M
P/E Ratio:
-16.31
EPS:
-0.35
Net Cash Flow:
$-68.07M
1W Performance:
-3.22%
1M Performance:
-28.98%
6M Performance:
+148.26%
1Y Performance:
+150.44%
1-Day Range:
$5.62
$5.865
1-Week Range:
$5.31
$6.22
52-Week Range:
$1.54
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
(415) 754-3517
Address
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Compare NUVB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
5.71 | 1.93B | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.48 | 119.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.91 | 82.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.16 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.98 | 42.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.43 | 38.60B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Forecasting The Future: 9 Analyst Projections For Nuvation Bio - Benzinga
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma - BioSpace
Nuvation Bio expands SIGMA trial to phase 3 for IDH1-mutant glioma - Investing.com Nigeria
Nuvation Bio announces pivotal global phase 3 Sigma trial (G203) for Safusidenib in IDH1-mutant glioma - marketscreener.com
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial for Safusidenib in IDH1-Mutant Glioma - Investing News Network
S P Trends: Is Nuvation Bio Inc stock undervalued right nowPrice Action & Long-Term Investment Growth Plans - baoquankhu1.vn
Nuvation Bio Inc. (NUVB) Stock Analysis: Exploring 111.55% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Nuvation Bio stock maintains Buy rating at B.Riley on Ibtrozi sales momentum - Investing.com Nigeria
Analyst Endorsements Of Ibtrozi Uptake Could Be A Game Changer For Nuvation Bio (NUVB) - Sahm
Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy (NYSE:NUVB) - Seeking Alpha
Assessing Nuvation Bio (NUVB) Valuation After Bullish Analyst Calls On Ibtrozi And mIDH1 Glioma Potential - Yahoo Finance
Turist Financial Remains a Buy on Nuvation Bio (NUVB) - Finviz
Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors - MSN
11 Best High Short Interest Stocks With Biggest Upside Potential - Insider Monkey
Nuvation Bio price target raised to $13 from $11 at Truist - Yahoo Finance
Truist Securities raises Nuvation Bio stock price target to $13 on Ibtrozi uptake - Investing.com Nigeria
Nuvation Bio Inc. (NUVB) price target lowered as IBTROZI sales meet expectations - MSN
Is Nuvation Bio Inc. stock undervalued right now2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - mfd.ru
Assessing Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Partnership Announcement - Sahm
JonesTrading Sticks to Their Buy Rating for Nuvation Bio (NUVB) - The Globe and Mail
JonesTrading Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12 - 富途资讯
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Nuvation Bio Inc. (NUVB) Stock Analysis: 97% Potential Upside with Promising Oncology Pipeline - DirectorsTalk Interviews
Nuvation Bio (NYSE:NUVB) Stock Price Down 4.2%Here's Why - MarketBeat
Why Nuvation Bio (NUVB) Is Down 8.2% After Expanding Global Taletrectinib Partnership With Eisai - simplywall.st
RBC Raises Price Target on Nuvation Bio to $12 From $9, Keeps Outperform, Speculative Risk - marketscreener.com
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations - Yahoo Finance
Top 10 Oncology Stocks to Buy Now - Insider Monkey
Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Insider Monkey
10 Stocks Under $10 with High Potential - Insider Monkey
Aug Closing: Whats the analyst consensus on Surrozen IncLong Setup & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Is Nuvation Bio (NUVB) Pricing In Its Sharp Swings Or A Long Runway For Growth - Yahoo Finance
Signal Recap: Should I invest in KORE Group Holdings Inc before earningsJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal - Yahoo Finance
A Look At Nuvation Bio’s Valuation After The Eisai Taletrectinib Collaboration Agreement - Sahm
Is Nuvation Bio Inc stock undervalued right nowMarket Growth Report & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Eisai and Nuvation Bio ink licensing deal for taletrectinib - The Pharma Letter
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib - Insider Monkey
Jones Trading raises Nuvation Bio stock price target to $12 on safusidenib study - Investing.com Nigeria
Jones Trading raises Nuvation Bio stock price target to $12 on safusidenib study By Investing.com - Investing.com Australia
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):